AOD-9604: What Clinicians Should Know

AOD-9604 is one of the more conceptually elegant peptides discussed in metabolic medicine, and also one of the most overstated. The idea is appealing on its face: take the part of growth hormone responsible for burning fat, leave out the rest, and you have a clean, targeted lipolytic agent without growth-hormone side effects. The science behind that idea is genuinely interesting. The human evidence behind the marketing is not nearly as strong — and the regulatory picture, as of 2024, is unambiguous. This page exists to keep those three things straight.

Patients who have plateaued on a growth-hormone secretagogue stack, or who want fat loss without the metabolic profile of GLP-1 agonists, increasingly ask about the AOD 9604 peptide. Being able to speak to it accurately — mechanism, evidence tier, and legal status — is part of practicing responsibly in anti-aging and regenerative medicine. This page is clinical education, not medical advice, and nothing here is a treatment recommendation, dosing protocol, or endorsement of any particular use.

What is AOD-9604?

AOD-9604 is a synthetic peptide derived directly from human growth hormone (GH). Specifically, it corresponds to the C-terminal fragment of growth hormone, amino acids 176–191. To understand why that matters, it helps to picture growth hormone as a molecule with several functional domains. The N-terminus drives growth. The middle region drives most of the IGF-1-mediated anabolic effects. And the C-terminus — that final stretch of the molecule — is the portion associated with fat metabolism.

AOD-9604 is, in essence, that fat-metabolism piece isolated and used on its own. The design logic was to capture growth hormone's lipolytic effect while deliberately leaving behind the growth-promoting and anabolic portions of the full hormone. The "AOD" in the name stands for anti-obesity drug, which reflects the original development intent rather than any achieved regulatory status. It is administered by subcutaneous injection.

The consequence of using only that fragment is the single most important fact about the compound: because AOD-9604 is not the whole hormone, it behaves very differently from the growth-hormone secretagogues it is often discussed alongside. It is not a GHRH analog like tesamorelin, and it is not a ghrelin mimetic. It sits in its own category, which is exactly why its role in a protocol is different.

How AOD-9604 works

The proposed mechanism of AOD-9604 is what makes it distinctive. Rather than acting on the pituitary or the growth-hormone axis at all, AOD-9604 is thought to act directly on fat tissue. The proposed pathway is stimulation of beta-3 adrenergic receptors in adipose tissue, which would promote lipolysis — the breakdown of stored fat — while also inhibiting lipogenesis, the formation of new fat. In short, the proposed effect is to push adipose tissue toward burning fat and away from storing it.

The defining feature of this mechanism is what it does not do. AOD-9604 does not bind growth-hormone receptors. Because of that, it does not raise IGF-1, the downstream mediator responsible for most of growth hormone's tissue effects. And because IGF-1 is not elevated, AOD-9604 does not produce the glucose dysregulation, insulin resistance, or other growth-hormone-related effects that accompany full secretagogues. You get, at least in theory, fat metabolism without an anabolic signal and without growth-hormone-axis consequences.

That same mechanism is also the source of its limitations, and this is where honest clinical reasoning matters. Because AOD-9604 carries no anabolic component, it does not directly stimulate muscle protein synthesis. It will not, on its own, build or preserve lean mass. For a clinician thinking about body recomposition — fat loss combined with lean-mass preservation — that means AOD-9604 cannot do the whole job. It addresses only the adipose side of the equation.

One practical upside of acting outside the growth-hormone axis is compatibility. Because AOD-9604 has no significant effect on the pituitary axis, it can run in parallel with a growth-hormone secretagogue protocol without interfering with the pulsatile growth-hormone dynamics those protocols depend on. The two operate on separate tracks: a secretagogue stack works through the GH–IGF-1 cascade, while AOD-9604 acts on adipocytes. That separation is the basis for the way AOD-9604 is most often discussed — as an adjunct rather than a standalone therapy.

The evidence reality

This is the section that the marketing around AOD-9604 tends to skip. It deserves to be stated plainly: the human efficacy evidence for AOD-9604 is thin. The compound sits at a low evidence tier — there is a reasonable preclinical base and some early human data suggesting a fat-loss signal, but that is a very different thing from established clinical efficacy.

The most important single data point is also the most inconvenient one for enthusiasts. A Phase IIb obesity trial — the study specifically designed to demonstrate weight loss — failed to meet its primary endpoint. There are no Phase III randomized controlled trial data supporting AOD-9604 as a weight-loss therapy. Put in context, this is a fraction of the evidence supporting established metabolic therapies, where large multi-trial programs have demonstrated outcomes. AOD-9604 is, by comparison, mechanistically interesting but clinically unproven.

That gap has direct implications for how a clinician should speak about the compound. Any discussion of AOD-9604 with a patient should reflect the evidence honestly. It should not be presented with the confidence of an established therapy. Language that matches the data — framing the evidence as early-stage, with a failed obesity endpoint, and any use as investigational — is the responsible posture. Overstating the case here is not a small error; it misrepresents a compound whose receptor story is much stronger than its clinical results.

Where AOD-9604 fits in a protocol

Given the mechanism and the evidence, the honest way to position AOD-9604 is as an adjunct, not a primary compound. The use cases discussed clinically are narrow: a patient who has contraindications to other metabolic agents, a patient who has plateaued on a growth-hormone secretagogue stack, or a patient seeking targeted fat loss without the broader metabolic effects of other therapies. In each case, AOD-9604 is one piece, not the whole plan.

The conceptual appeal lies in pairing. Because AOD-9604 addresses only fat metabolism and contributes no anabolic signal, it is sometimes combined with a growth-hormone secretagogue stack so that one element handles lipolysis in adipocytes while the other supports lean mass and connective tissue through the GH–IGF-1 pathway. The two do not compete for receptors and do not suppress each other, which is why this kind of pairing is discussed for body-recomposition goals that neither component could reach alone. The compound's roughly short duration of action and its timing relative to food are also clinically relevant, but those are exactly the specifics that belong with a qualified prescriber and structured training rather than a web page.

There is one piece of patient counseling that matters more than any protocol detail. AOD-9604 is not a weight-loss drug in the way patients tend to imagine. Its proposed effect is on adipose metabolism, particularly visceral and abdominal fat. Even where it reduces a fat depot, that does not automatically translate into scale weight loss, and the effect depends on the patient doing the rest of the work — a caloric deficit and resistance training. The receptor needs a substrate to act on. A patient who expects AOD-9604 to substitute for diet and exercise has misunderstood what the compound does, and correcting that expectation up front is part of responsible care.

Regulatory status

Here the picture is clear, and it is the most important practical fact on this page. AOD-9604 is not FDA-approved for any indication. Beyond that, recent regulatory action has specifically foreclosed the compounding route that once made it accessible.

The sequence matters. AOD-9604 was removed from FDA compounding Category 2 in September 2024. Removal from Category 2 does not, by itself, create a legal compounding pathway — it simply opens the door to review by the Pharmacy Compounding Advisory Committee (PCAC), which decides whether a compound moves into Category 1. In December 2024, PCAC voted against AOD-9604, closing the door to a Category 1 listing. The result is unambiguous: there is no current 503A compounding pathway for AOD-9604.

The clinical implication follows directly. Because there is no legitimate compounding path and no FDA approval, AOD-9604 encountered in practice today is typically sourced from gray-market or non-compliant pharmacy operations. That sourcing reality introduces serious, separate concerns around identity, purity, and sterility — concerns that exist independently of anything about the molecule's biology. A clinician evaluating AOD-9604 has to weigh not only the thin efficacy evidence but also a sourcing environment that the regulatory system has explicitly declined to legitimize.

What proper training covers

Sound peptide education does not stop at a compound's mechanism — and AOD-9604 is the clearest example of why. A clinician can fully understand the lipolytic story and still mishandle the compound by overstating its efficacy or failing to grasp its regulatory and sourcing reality. The most valuable skill is the ability to hold mechanism, evidence tier, and legal status separately and reason across all three honestly.

Empire's peptide curriculum is built around exactly that judgment. It situates individual peptides within the broader science of peptide therapy, teaches how to read evidence tiers and interpret regulatory decisions, and addresses compliant sourcing and honest patient communication. It is part of the larger Academy of Anti-Aging & Functional Medicine. For a foundational overview, providers often start with what peptide therapy is and related growth-hormone-axis peptides such as ipamorelin & CJC-1295 and tesamorelin before going deeper.